Lundbeck Inc.'s antidepressant Brintellix (vortioxetine) has become the latest new drug approved by China FDA.
The approval for the treatment for severe depression is significant with China, which is increasingly aware of the disease burden...
China FDA greenlights Lundbeck's Brintellix for severe depression, and more new drug approvals may be on the way. Physician education will be key for Brintellix, given relatively low number of psychiatrists in China.

Lundbeck Inc.'s antidepressant Brintellix (vortioxetine) has become the latest new drug approved by China FDA.
The approval for the treatment for severe depression is significant with China, which is increasingly aware of the disease burden...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
<p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>
<p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>